Videos

Carnaby says prophylactic gastrostomy tube placement may not be as supportive as previously thought in the health of the muscles in these patients.

Bible says most oncologists would consider lenvatinib as a first-line therapy for patients who require systemic therapy where there are not suitable, focal palliative options.

"This combination seems to be well-tolerated by patients with manageable toxicity, and overall efficacy for the small group seems to be favorable."

Cohen says while the data from the study looking at nivolumab has not been released yet, the halting of the trial due it having met its primary OS endpoint likely means good news.

Cabanillas says her and her team set a goal of reducing the time between when they are contacted about a patient with anaplastic thyroid cancer, and when the patient is given an appointment time, to fewer than 5 business days.

Zevallos says that while HPV-positive oropharyngeal SCC has a positive outcome for patients, smoking status should be taken into account for these patients when making a decision to deintensify therapy.

Melotek says the trial's primary endpoint was comparison of efficacy when cetuximab is added to both therapies with historical control, with a secondary endpoint being further investigation of the usefulness of both chemotherapy platforms.

mCRC with Tanios Bekaii-Saab, MD and Tara Seery, MD

Hoffman-Censits says atezolizumab has recently undergone a phase II clinical trial for patients with bladder cancer who failed platinum-based chemotherapy.

Seiwert says in general, immunotherapies produce a response rate of between 20- to 25%, 1 in 4 patients respond, and the treatment type is equally effective in both HPV-positive and HPV-negative disease.

Zevallos says the study consisted of 66 patients and found that there were distinct genomic differences between HPV-positive smokers and non-smokers.

The two platforms involved in the study were the FHX regimen and a cisplatin radiation approach with accelerated radiation. Siltuximab was also used in the study as induction chemotherapy alongside carboplatin and paclitaxel.

Whitworth says that while it is generally perceived that the ER-positive/HER2-negative breast cancer patient population is the luminal subtype, 1 of every 5 of those patients would actually considered basal subtype.

Bear discusses studies adding treatments to chemotherapy in order to increase the pathological complete response (pCR) rate and the difficulties of translating those benefits into better overall survival (OS) rates for patients with breast cancer.

Winer says patients who do well on carboplatin and show both a good pathologic complete response and good disease free survival may be patients who have refractory disease and are responding well to the treatment, while others may be patients who were bound to do well regardless.

Seidman says currently there is not a HER2 histochemical test for gene amplification or signatures to best select patients for either CDK46 or MTOR inhibitor, as well for PI3 kinase inhibition.

Sharpe, whose lab aided in the discover of the pathway, says blocking the pathway in order to treat cancers is important because it allows T cells to work better.

Yardena Samuels, PhD, on the ineffectiveness of targeting a single gene of proteins in patients with melanoma. Samuels says this strategy may work for the short term for treatment, but patients would tend to develop a resistance much quicker to treatment strategies using this method.

Holmen says that utilizing targeted therapies could potentially be the answer, though clinically-tested combinations have historically not done as well as clinicians had hoped.

Randolph says pre-operative loss of voice tracks "robustly" with invasive thyroid cancer, and being aware of this issue before surgery helps surgeons better treat their patients.